Editor's note

This article was originally published on 4 August 2014 as part of the VacZine Analytics ExpertREACT series. It is reproduced here for archival purposes. Market conditions, pipeline statuses and regulatory positions described reflect the state of knowledge at that date.

2014: a year of vaccine M&A

2014 proved to be an unusually active year for vaccine sector M&A. GSK's April announcement of its acquisition of the Novartis vaccines business (excluding influenza) for $5.25 billion set a high watermark. In late July, Pfizer announced it had acquired Baxter International's portfolio of marketed vaccines for $635 million. The Baxter vaccines business generated just below $300 million in 2013, representing approximately 2% of Baxter's total sales.

Acquisition Price
$635m

Pfizer's acquisition of Baxter's vaccine portfolio, adding NeisVac-C and FSME-Immun to its franchise

Key acquired products

The two main products acquired were NeisVac-C, a meningococcal serogroup C vaccine, and FSME-Immun, a vaccine against tick-borne encephalitis (TBE). FSME-Immun was estimated to generate approximately $184 million in 2013 and holds market leadership in TBE - a position likely to be cemented in the near term given the disruption of Novartis' Encepur operations as a consequence of the GSK transaction. Pfizer also acquired an interest in Baxter's manufacturing facility in Orth, Austria.

Logic and limitations

Pfizer's vaccine division had remained essentially a one-product company since acquiring Wyeth in 2009, deriving essentially all revenues from Prevnar/Prevenar-13. An attempted acquisition of AstraZeneca (which would have included FluMist/Fluenz) was abandoned in May 2014. The Baxter deal is explicitly low-risk - both NeisVac-C and FSME-Immun enjoy stable competitive dynamics unlikely to change materially over the next decade.

Notably, Pfizer did not acquire Baxter's Lyme disease programme or influenza business - both considered too high-risk for Pfizer's conservative acquisition profile. The meningococcal C market exit and re-entry (Pfizer divested Meningitec to Nuron in December 2012 before now re-entering with NeisVac-C) will raise eyebrows, but appears to be opportunism spurred by GSK's aggressive Novartis move.

"Pfizer has re-entered a market segment it previously exited - the logic must lie in opportunism driven by a rival's transformative deal."